Clinical Trials Browser

Phase 1 × talazoparib × Gastrointestinal × Clear all

NCT04511039 2026-03-02

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Phase 1 Recruiting

45 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04672460 2024-09-25

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Phase 1 Completed

73 enrolled 18 charts

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT01286987 2019-01-10

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Phase 1 Completed

113 enrolled 39 charts

BreastClassical hematologyGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma

NCT02567396 2017-04-24

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Phase 1 Withdrawn

BreastGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms